Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 16;7(4):328-337.
doi: 10.1016/j.wjorl.2020.05.010. eCollection 2021 Oct.

Tranexamic acid in otorhinolaryngology - A contemporary review

Affiliations
Review

Tranexamic acid in otorhinolaryngology - A contemporary review

Jordan Fuzi et al. World J Otorhinolaryngol Head Neck Surg. .

Abstract

Tranexamic acid (TXA) is an anti-fibrinolytic agent which has been proven beneficial in multiple surgical specialties where significant bleeding can occur. Whilst it has been widely available for over 40 years its use within Otorhinolaryngology is still limited. Operations in Otorhinolaryngology are particularly varied with some such as tonsillectomy having the potential for significant life threatening bleeding. Other operations are performed within small confined surgical fields and even small amounts of bleeding can significantly detriment surgical field and increase technical difficulty and operative time. This review evaluated the current literature on the benefits of tranexamic acid within the field of Otorhinolaryngology and Head and Neck Surgery. Overall TXA was demonstrated to be a safe drug with no major adverse effects including thromboembolic events reported in any study. It has been shown to be of particular benefit in rhinology by improving surgical field, reducing operative time and reducing postoperative swelling and ecchymosis. The benefit in tonsillectomy is less clear and further studies are required to evaluate its potential use in the reduction of post tonsillectomy haemorrhage rates.

Keywords: Bleeding; Otorhinolaryngology; Surgery; Tranexamic acid.

PubMed Disclaimer

Conflict of interest statement

None.

Similar articles

Cited by

References

    1. Lowe D., Meulen J.H.P.V.D. National prospective tonsillectomy audit. Bull R Coll Surgeons Engl. 2003;85:352–353.
    1. Shakur H., Beaumont D., Pavord S., Gayet-Ageron A., Ker K., Mousa H.A. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database Syst Rev. 2018;2:CD012964. - PMC - PubMed
    1. Ker K., Roberts I., Shakur H., Coats T.J. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2015:CD004896. - PubMed
    1. Gausden E.B., Qudsi R., Boone M.D., OʼGara B., Ruzbarsky J.J., Lorich D.G. Tranexamic acid in orthopaedic trauma surgery: a meta-analysis. J Orthop Trauma. 2017;31:513–519. - PMC - PubMed
    1. Franchini M., Mengoli C., Marietta M. Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials. Blood Transfus. 2018;16:36–43. - PMC - PubMed